LONDON, June 4 (Reuters) - AstraZeneca's lung cancer therapy, Tagrisso, cut the risk of death by more than half in patients with a certain form of lung cancer who were diagnosed early enough to have ...

After a massive tumor progression showing, AstraZeneca hopes new life extension data could expel whatever doubt that remains for using Tagrisso early in non-small cell lung cancer (NSCLC). Using ...

Tagrisso following chemoradiotherapy improved progression-free survival compared with placebo in stage 3 EGFR-mutated non–small cell lung cancer. Patients with locally advanced, unresectable (not able ...

The FDA will speed up its review of Tagrisso plus chemotherapy for patients with advanced or metastatic EGFR-mutant non-small cell lung cancer after the regimen led to improved outcomes in a phase 3 ...

AstraZeneca’s Tagrisso is already swimming in billions in annual sales after setting a new standard for treating metastatic EGFR-mutant non-small cell lung cancer. And now, with an FDA go-ahead in ...

AstraZeneca presented data from the AURA3 trial that data is supportive of Tagrisso (osimertinib) potentially becoming the new standard of care for 2nd-line treatment of patients with epidermal growth ...

Results underscore TAGRISSO as 1st-line standard of care and backbone therapy in EGFRm lung cancer across stages WILMINGTON, Del.--(BUSINESS WIRE)-- Positive results from the final overall survival ...

Around 30,000 people annually in the U.S. with non-small cell lung cancer (NSCLC) also get diagnosed with specific epidermal growth factor receptor (EGFR) gene mutations, a condition that affects ...

TAGRISSO ® (osimertinib) 40mg and 80mg once daily oral tablet has been approved in over 45 countries, including the US, EU, Japan and China, for patients with EGFR T790M mutation-positive advanced non ...

Results showed treatment with osimertinib reduced the risk of disease progression or death by 84% compared with placebo. The Food and Drug Administration (FDA) has approved Tagrisso ® (osimertinib) ...